Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy.
This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com
📻 Siste episoder av COR2ED - Oncology Medical Conversation Video
Her er de nyeste episodene tilgjengelige via RSS-feeden:
Laster episoder...
📱 Slik abonnerer du på COR2ED - Oncology Medical Conversation Video
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification (00:25:03)
Understanding HER2-low and HER2-ultralow classification in mBC
In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice.
The experts explore:
Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework
The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template
When and why to perform re-biopsy to detect changes in HER2 expression over time
Best practices for monitoring and managing T-DXd–related adverse events, including nausea, vomiting, fatigue and ILD/pneumonitis
Watch now to deepen your understanding of HER2-low and HER2-ultralow classification, refine how and when you test, and appreciate the impact on therapeutic decision-making in mBC.
Clinical takeaways
DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for HER2-low and HER2-ultralow mBC, improving PFS and OS and showing that even minimal HER2 expression can identify patients who benefit from T-DXd
Current CAP reporting template separates HER2-low (IHC 1+ or 2+/ISH–) and HER2-ultralow (IHC 0 with faint or incomplete membrane staining in ≤10% of tumour cells) from true HER2-0, creating treatment-defining strata for HER2-targeted ADCs such as T-DXd
Because HER2 expression is dynamic between primary and metastatic sites and over time, re-biopsy at progression, particularly in tumours previously scored as HER2-0, should be considered to identify new candidates for T-DXd
T-DXd delivers substantial antitumour activity, but treatment-related adverse events, including nausea, vomiting, fatigue, alopecia and, in particular, ILD/pneumonitis, require careful and proactive management. Clinicians should apply structured supportive care and early, vigilant monitoring to ensure safe and sustained treatment
This is the full video. Watch the shorter highlights video here: https://youtu.be/3xepcF70Ljw
Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/breastcancerconnect/
X: https://x.com/BreastCaConnect
This content is intended for healthcare professionals only.
This programme is supported by an Independent Education Grant from AstraZeneca.
This podcast is developed by cor2ed.com
Published December 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Understanding EP-NEC: Through Diagnosis, Treatment, and Support (00:27:28)
In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.
They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.
Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.
Key clinical takeaways:
Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments
While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise
Accessing a support network can provide emotional reinforcement and information for patients and their care partners
You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0
Or watch on YouTube: https://youtu.be/nfng2s3jSw8
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true
X:https://x.com/net_connectinfo
This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.
This podcast is developed by cor2ed.com
Published in November 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Exploring the role of targeted radiopharmaceutical treatment in NETs (00:21:56)
How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?
In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.
As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.
Key clinical takeaways:
Pair the right patient with the right treatment using an understanding of the key clinical studies
The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data
The best outcomes are achieved through multi-disciplinary collaborations that include the patient
Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true
X: https://x.com/net_connectinfo
This content is intended for healthcare professionals only.
This podcast is supported by an Independent Education Grant from ITM.
This podcast is developed by cor2ed.com
Published September 2025
Tackling mPDAC: chemotherapy strategies that matter (00:21:51)
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.
This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.
Key clinical takeaways:
mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible
Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles
Choice of 2nd line treatment should be guided by prior regimen and patient fitness
Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events
You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0
Or watch on YouTube: https://youtu.be/8YxRnjOYUv4
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/giconnect
X: https://x.com/giconnectInfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Ipsen USA.
This podcast is developed by cor2ed.com
Published May 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Understanding Rare NSCLC Mutations: Insights, access and support (00:20:34)
Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.
As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.
Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey.
What does the patient pathway look like from both perspectives? What are the needs of Medical Oncologists and patients when navigating the treatment journey? What do patients need from their oncologists? What do oncologists think their patients need from them? Are these needs matched by the support currently available?
You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0
Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t
Follow LUNG CONNECT on social media:
X – https://x.com/lung_connect
LinkedIn – https://www.linkedin.com/company/lungconnect/
This content is intended for healthcare professionals only.
The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.
This podcast is developed by cor2ed.com
Published on May 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
The HER2 diagnostic and treatment landscape in NSCLC (00:18:36)
Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC
This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.
In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC.
The conversation unfolds to cover;
How to distinguish HER2 alterations from other alterations on biomarker reports
The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC
The potential CNS activity of these treatments in patients with HER2-mutated NSCLC
How the treatment pathway may look in the near future
You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/
Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y
Follow LUNG CONNECT on social media:
X – https://x.com/lung_connect
LinkedIn – https://www.linkedin.com/company/lungconnect/
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Bayer.
This podcast is developed by cor2ed.com
Published on May 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
The HER2 Diagnostic and Treatment Landscape in NSCLC (00:21:25)
Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives
This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.
What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos.
In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 alterations may be translated in the community setting.
Listen to different expert perspectives on
The different HER2 alterations and prevalence in NSCLC
Which technique to identify which HER2 alteration
HER2-targeted treatments, both approved and in development
You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-1/?media=1
Or watch on YouTube: https://youtu.be/3vMCzR1jqbI
Follow LUNG CONNECT on social media:
X – https://x.com/lung_connect
LinkedIn – https://www.linkedin.com/company/lungconnect/
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Bayer.
This podcast is developed by cor2ed.com
Published on April 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses (00:13:43)
In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups.
Key topics include
Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET
Clinical implications of the EMERALD subgroup analyses
Review of elacestrant's safety profile
Clinical takeaways
Duration of prior ET + CDK4/6i ≥12 months was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC endocrine monotherapy in patients with ESR1-mut, ER+/HER2– metastatic breast cancer
The PFS benefit associated with elacestrant was consistent across clinically relevant subgroups evaluated, including patients with bone metastases, liver and/or lung metastases, n<3 or ≥3 metastatic sites or tumors with PIK3CA-mut, TP53-mut, HER2-low tumor expression, or ESR1-mut variants D538G or Y537S/N
Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs and without evidence of the toxicities associated with other drug classes, such as CDK4/6i and PI3K/AKT/mTOR inhibitors
These data support current guidelines that recommend routine testing for the emergence of ESR1-mut in ctDNA at each disease progression
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
This video was developed by https://cor2ed.com/
Published March 2025
Best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer (00:26:13)
This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.
Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.
Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.
Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes.
Key clinical takeaways:
Molecular testing, especially for biomarkers like ESR1 and PI3 kinase, is a critical component in guiding treatment decisions, particularly in second-line therapy for HR+ HER2- metastatic breast cancer.
Liquid biopsy is a valuable tool for ongoing monitoring of metastasis and detecting mutations like ESR1 during disease progression, but tissue biopsies may yield more reliable results for certain mutations like PI3 kinase alterations present early in cancer development.
Testing for a broad range of mutations, such as PI3 kinase, AKT, PTEN, ESR1, MSI, and NTRK, allows for the identification of actionable mutations and eligibility for newer targeted therapies, especially in second and third-line treatments.
Clinicians must be familiar with the specifics of the assays used to test for mutations, as different methods and testing conditions can impact results.
You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/precision-oncology-connect/programmes/molecular-testing-targeted-therapy-metastatic-breast-cancer/?media=0
Or watch on YouTube: https://www.youtube.com/watch?v=CTnXmh1oDwQ
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/ntrk-connect/
X: https://x.com/PresOnc_Connect
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Thermo Fisher Scientific.
This podcast is developed by cor2ed.com
Published March 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions (00:11:28)
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions
Key clinical takeaways:
MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions
ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations
Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting
Shared decision-making, supported by patient education, is essential for optimising treatment outcomes
The treatment landscape for advanced and recurrent endometrial cancer (EC) is evolving, with molecular classification playing a key role in guiding decisions. In this podcast, Prof. Xavier Matias-Guiu (Pathologist) and Dr Jurjees Hasan (Medical Oncologist) discuss the latest advancements in personalised treatment approaches for EC.
Key topics include:
The role of molecular classification in guiding treatment selection and testing strategies
Treatment options for patients with pMMR status
Effective patient communication for shared decision-making
Tune in for expert insights and practical guidance to optimise treatment strategies in advanced and recurrent EC
You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/obstetrics-gynecology-connect/programmes/endometrial-cancer-molecular-classification-treatment-decisions/
Or watch on YouTube: https://youtu.be/KvYIB7PBpyQ
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/ob-gyn-connect/?viewAsMember=true
X: https://x.com/OBGynConnect
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this podcast.
This podcast is developed by cor2ed.com
Published February 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Intermediate HCC – The evolving role of IO (00:27:12)
Intermediate HCC – The evolving role of IO
In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC. The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.
Joined by Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist) and Ed Kim (interventional radiologist), the experts provide a brief overview of current treatment options for intermediate HCC, addressing its heterogeneity and standard treatment pathways. They delve into the latest clinical trial data (EMERALD-1, LEAP-012) on combining IO with loco-regional therapies, discussing clinical implications. The conversation also underscores the importance of effective collaboration within the multidisciplinary team for delivering optimal patient care. The episode concludes with future perspectives in the field and key clinical takeaways on integrating IO with loco-regional therapy and the significance of multidisciplinary care in managing HCC.
Key clinical takeaways:
IO and IO-based treatments are moving earlier in the treatment paradigm for patients with intermediate HCC. Earlier integration of these therapies aims to achieve improved systemic control, allowing loco-regional therapy to target oligoprogression, residual lesions or reduce tumour burden
Emerging data supports combining systemic and loco-regional therapies for patients with intermediate HCC. EMERALD-1 and LEAP-012 show promising PFS data using IO-based combination regimens like durvalumab + bevacizumab or pembrolizumab + lenvatinib alongside TACE. Long-term OS data are awaited
Effective communication and coordinated care among specialists, such as medical oncologists, radiation oncologists, hepatologists, and interventional radiologists, are essential to developing optimal treatment strategies for patients with intermediate HCC
You can also watch a video of the experts in conversation and download the accompanying slides and transcript on our website: https://cor2ed.com/hcc-connect/programmes/intermediate-hcc-the-evolving-role-of-io/
Or watch on YouTube: https://www.youtube.com/watch?v=3voWa0U96lE
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/hcc-connect/
X https://x.com/hccconnectinfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.
This podcast is developed by cor2ed.com
Published on January 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. <...
Intermediate HCC – treatment options and strategies (00:20:19)
In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr Emil Cohen to explore the complexities of managing intermediate-stage hepatocellular carcinoma (HCC). Together, they unpack treatment options and strategies through a dynamic and engaging discussion rooted in real-world clinical practice.
Key topics include:
An overview of the available treatment options for this heterogeneous patient population with intermediate HCC
A deep dive into loco-regional therapies, including TACE, TARE (Y-90), and SBRT
Exploring the role of systemic treatments in patients with intermediate HCC and the use of multimodal treatment approaches, combining loco-regional treatment options with systemic treatments
The importance of the multidisciplinary care team for the treatment of intermediate HCC
Key clinical takeaways:
Defined by guidelines, treatment options for patients with intermediate HCC include liver transplantation, loco-regional therapies, and systemic therapy. Treatment selection depends not only on tumour burden and liver function, but also on practical considerations in clinical practice
Systemic therapies are being evaluated earlier in the disease course, particularly for intermediate HCC, either as standalone treatments or in combination with loco-regional therapies
Ongoing clinical trials, such as REPLACE and ABC-HCC, aim to clarify the role of systemic therapies in intermediate HCC as standalone options, while others, like EMERALD-1 and LEAP-012, focus on their use in combination with loco-regional approaches
Adverse events require identification of the specific adverse events profile. Regardless of origin (systemic or loco-regional), complications must be resolved to maintain treatment efficacy and ensure patient safety
Optimal care for intermediate HCC relies on a multi-disciplinary team, including hepatologists, interventional radiologists, radiation oncologists, surgeons, and medical oncologists
Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/hcc-connect
X: https://x.com/hccconnectinfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.
This podcast is developed by cor2ed.com
Published January 2024
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch (00:26:18)
Join the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast series, this episode dives into 2nd line treatment selection in advanced HCC and the key considerations for deciding when to switch therapies.
Topics include:
2nd line options for advanced HCC after 1st line TKIs and IO-based therapies
Sequencing strategies and clinical practice approaches
Key data supporting 2nd line decisions
Factors to consider when transitioning to 2nd line therapy
Key clinical takeaways:
Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions
When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life.
Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered
Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management
Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation
Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/hcc-connect
X: https://x.com/hccconnectinfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.
This podcast is developed by cor2ed.com
Published December 2024
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Testing to treatment of BRAF-mutant metastatic NSCLC (00:23:22)
Testing to treatment of BRAF-mutant metastatic NSCLC
In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients.
The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients. Various treatments are considered, along with which decision criteria come into play when selecting a particular treatment.
The experts also discuss how to treat patients who have co-mutations detected during testing.
This is an informative podcast that culminates in some interesting key messages from two well-recognised Experts in the field of NSCLC.
Key clinical takeaways:
Test all patients irrespective of histology and smoking history
Test upfront so that more efficacious agents can be used earlier in the patient journey
Next-generation sequencing is the gold-standard for testing wherever possible to ensure various targetable alterations are not missed
There are effective BRAF + MEK inhibitor combination treatments available to treat our BRAFv600E-mutant metastatic NSCLC patients which have manageable safety profiles
Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/UZPBUAFOwcY
Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/lung-connect/programmes/testing-treatment-braf-mutant-metastatic-nsclc/
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/lungconnect/
X: https://x.com/lung_connect
This content is intended for healthcare professionals outside of the UK & ROI only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
This podcast is developed by https://cor2ed.com/
Published November 2024
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
HCC podcast series part 1: The use of IO in unresectable HCC (00:23:21)
In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include:
Current first-line systemic treatment options for uHCC
Efficacy and safety of IO and IO combinations including practical aspects of identifying and managing immune-mediated AEs
How to select between the two first-line IO-based treatment options based on clinical factors and practical considerations
Key clinical takeaways:
Two first-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape
Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies
Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen ( single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up
IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary.
In clinical practice, treatment choice should be individualized, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/hcc-connect
X: https://x.com/hccconnectinfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.
This podcast is developed by cor2ed.com
Published on November 2024
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
BRAF-mutated CRC: testing to treatment (00:25:47)
Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments for these patients.
They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.
Several key trials are discussed, including the BEACON trial which resulted in encorafenib plus cetuximab being the standard of care in the second-line setting for patients with BRAF mutated CRC.
The discussion also looks at future studies including the BREAKWATER trial, which will provide important information about encorafenib plus cetuximab in the first-line for these patients, as well as the SEAMARK trial which will show the effects of adding immunotherapy to this combination.
Key clinical takeaways:
BRAF mutations occur in around 10% of colorectal cancer patients and patients harbouring these have aggressive disease and a poor prognosis
Targeted therapies are available for BRAF-mutated CRC so it is important to test patients early in their disease preferably with next-generation sequencing
Encorafenib plus cetuximab are established as the standard of care in the second-line setting for BRAF-mutated CRC
Doublet chemotherapy plus anti-VEGF is currently the preferred treatment in the first-line. The BREAKWATER trial will determine whether the combination of encorafenib plus cetuximab is a suitable first-line treatment option
Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/Pp7oAI9JW4A
Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/gi-connect/programmes/braf-mutated-crc-testing-treatment/
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/giconnect
X: https://x.com/giconnectInfo
This content is intended for healthcare professionals outside of the UK & ROI only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
This podcast was developed by https://cor2ed.com/
Published November 2024
In this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making, between patient and physician.
The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions.
Prefer to watch and listen? Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/?media=1
Watch the full video on YouTube https://youtu.be/2JYuPhc2jHg
Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k
Follow us on social media
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect
X: https://x.com/net_connectinfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen
This podcast is developed by cor2ed.com
Published July 2024
In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication and collaboration during consultations. This can include how to make a patient feel as comfortable and in control as possible, as well as recognising their goals and concerns.
The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET treatment options in daily life.
NETs are complex, rare diseases. Optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. Are you aware of how healthcare practitioners and patients can share decision- making? Or the recent data on how patients prefer to receive treatment?
In this first episode of a two-part podcast series, Dr Mohid S Khan and NET patient Sally Jenkins discuss shared decision-making in NET consultations and ways to help the patient in their journey.
Prefer to watch and listen? Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/
Watch the full video on YouTube https://youtu.be/YgqrEnSePWg
Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k
Follow us on social media
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect
X: https://x.com/net_connectinfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen
This podcast is developed by cor2ed.com
Published July 2024
Regional differences in NET: Treatment and future developments (00:21:16)
In the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future developments in the field which may help to improve patient outcomes. The episode includes information on different treatment options and modalities, and well as best practice on identifying which patients may benefit most from particular treatments using available biomarkers.
Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-2/
Or go to the video on YouTube: https://youtu.be/zd_JvUmIhFg
We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.
This podcast is developed by cor2ed.com
Regional differences in NET: Epidemiology, diagnosis, and referral strategies (00:21:47)
In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future developments.
NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional differences can impact these? In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, patient pathways, as well as look to future developments.
Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-1/
Or go to the video on YouTube: https://youtu.be/6fKAxS4u-2o
We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.
This podcast is developed by cor2ed.com
Understanding the needs of different patient populations in colorectal cancer (00:25:26)
Do you understand the needs of different patient groups with colorectal cancer? Do you know about the barriers to treatment experienced by different ethnicities, socioeconomic groups and younger patients? In this insightful podcast facilitated by Oncology Brothers Drs Rahul and Rohit Gosain, Prof Tanios Bekaii-Saab and Ms Deneen Richmond provide their perspectives as a practising oncologist and a cancer survivor.
They discuss the different methods of communication required to build trust in patients from specific ethnic groups (African American, Hispanic and Asian American). They also talk about the unique challenges experienced by younger patients with colorectal cancer. Throughout the podcast the experts emphasise the importance of screening to facilitate early diagnosis and treatment.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/patient-populations-colorectal-cancer/
Or go to the video on YouTube: https://youtu.be/o-lr54-D9_g
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.
This educational podcast is developed by cor2ed.com
Interpreting real-world evidence in later-line mCRC (00:27:54)
What are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be used to complement data from clinical trials?
In this podcast, GI oncologists Prof. Tanios Bekaii-Saab and Prof. Shubham Pant discuss how to interpret real-world evidence in later line metastatic colorectal cancer. They also discuss data from ASCO GI 2024 and how these results can be used to inform treatment decisions.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/real-world-evidence-mcrc/
Or go to the video on YouTube: https://youtu.be/knQcsWVqcSA
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.
This educational podcast is developed by cor2ed.com
Cáncer de ovario: dificultades en la fase preanalítica y pruebas de biomarcadores (00:32:22)
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Usted está viendo el tercer episodio de una serie de podcast de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará a la profesora adjunta Martina Murphy (médica oncóloga) y a la profesora adjunta Caterina Marchiò (anatomopatóloga) hablar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores en el cáncer de ovario.
A medida que se desarrolla la conversación, las expertas explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de ovario y hablan sobre los mejores métodos para minimizar las dificultades preanalíticas.
¿Prefiere ver el video mientras escucha?
Vea el video de la conversación de los expertos y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-ovario-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/
O acceda al video en YouTube: https://youtu.be/HnYacC0wZp0
Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP). Puede obtener más información sobre la AMP en www.amp.org.
Los expertos médicos en este podcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics. Este podcast fue creado por cor2ed.com
Câncer de ovário: Desafios da fase pré-analítica e teste de biomarcadores (00:32:22)
Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de ovário e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está assistindo à parte 3 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá a Professora Adjunta Martina Murphy (oncologista) e a Professora Adjunta Caterina Marchiò (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de ovário.
Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de ovário e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.
Prefere assistir enquanto escuta?
Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-ovario-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/
Ou veja o vídeo no YouTube: https://youtu.be/tiUgtzqMD-Q
Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP). Saiba mais sobre a AMP em www.amp.org
Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics. Este podcast é desenvolvido pela cor2ed.com
Câncer de pulmão: Desafios da fase pré-analítica e teste de biomarcadores (00:27:48)
Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de pulmão e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está assistindo à parte 2 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá a Dra. Bruna Pellini (oncologista) e Semir Vranić (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de pulmão.
Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de pulmão e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.
Prefere assistir enquanto escuta?
Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-pulmao-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/
Ou veja o vídeo no YouTube: https://youtu.be/lmwt0UVitF4
Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP). Saiba mais sobre a AMP em www.amp.org
Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics. Este podcast é desenvolvido pela cor2ed.com
Side 1 av 1
COR2ED - Oncology Medical Conversation Video - Gratis RSS Feed for Norsk Podcast | OpenPodMe | OpenPodMe - Åpen RSS for Norske Podcaster
